 PRESS RELEASE STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLAs position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications Geneva, SWITZERLAND 9 January 2023, STALICLA SA, a clinical-stage biotech company... The post STALICLA signs exclusive in-licensin... 